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older adults Methods: Medicare beneficiaries participated in the 2007 HRS pre-
scription drug survey and 2009 HRS well-being survey and enrolled in Medicare part 
D (stand-alone), HMO, fee-for service or Advantage plans. The study sample includes 
773 individuals with at least one of four common chronic health conditions and 
responded both years. Random intercept logit model was estimated for medica-
tion non-adherence and population based generalized estimating equation was 
utilized to examine poverty-adjusted well-being (excluding out-of-pocket medical 
expenditure from poverty threshold) Results: Preliminary results indicate that 
individuals having inertia in plan switching were 3.4 times more likely to be non-
adherent to regular prescription medications compared to those without inertia 
(odds ratio estimate, 3.4 with p< 0.001). Neither switching from brand name drug to 
generic drug plan nor plan level switching appeared to be a significant predictor of 
medication non-adherence or economic well-being in this group. ConClusions: 
Consumer inertia rather switching decision appears to be a significant factor influ-
encing medication non-adherence among individuals with four common chronic 
health conditions
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ComPlianCe and Control of HyPertension WitH Co-morbidities in 
Primary Care in Ukraine
Korzh O.
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objeCtives: The aim of this study was to evaluate adherence of family doctors to 
National Clinical Practice Guideline (2012) in the management of hypertension with 
co-morbidities in Ukraine. Methods: Cross-sectional study was done at a primary 
care network in Ukraine. Total 62 physicians and 1550 patients’ prescriptions written 
by same physicians (25 prescriptions per physician) were analyzed. All patients had 
hypertension with co-morbidities. Depending on the recommendations of National 
Clinical Practice Guideline (2012), the prescriptions were clustered as compliant and 
non-compliant prescriptions. All obtained data were analyzed using descriptive 
and inferential statistics. Results: A statistically significant negative association 
(r= -0.089, p= 0.005) was observed between hypertension control and co-morbidities. 
Compliant patients had statistically weak negative association (r= -0.078, p= 0.015) 
with patients having co-morbidities (38.2%). No statistically significant association 
was observed between guideline adherence and any other co-morbidity. Majority 
of the patients received guidelines-compliant pharmacotherapy. The overall good 
level of physician compliance with National Clinical Practice Guideline (2012) was 
observed in the management of hypertension with co-morbidities. ConClusions: 
The study explored several features of prescription pattern of the primary care 
physicians involved in the management of hypertension with co-morbidities and 
recognized the need for improvement in their prescription pattern for treating the 
hypertension.
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objeCtives: EQ-5D and SF-6D can both be used to derive health utility scores. 
Variations in utility scores can have a major impact on the results of cost-util-
ity studies. This study aimed to compare the health utility of acute coronary 
syndrome (ACS) patients from Malaysia measured by the two descriptive sys-
tems Methods: Data was obtained from an earlier study. The study collected data 
from ACS patients admitted to the Sarawak General Hospital who consented to 
the study. Validated language versions of the EQ-5D-3L and SF-36v1 were admin-
istered during admission and 12-months post-admission. Health utility scores 
were calculated using the Malaysian EQ-5D-3L utility tariff and Brazier SF-6D 
algorithm. Patient demographic and clinical data were extracted from medi-
cal records. Results: Data from 100 of 112 subjects were usable for analysis. 
Mean age of patients was 56.3 years and 88% were male. Utility scores meas-
ured by EQ-5D were higher than those measured by SF-6D. Mean utility scores 
from EQ-5D and SF-6D during admission were 0.75 and 0.56 (p< 0.0001); and 0.82 
and 0.79 (p= 0.0521) 12 months post-admission, respectively. Improvement in 
utility scores from baseline to 12 months was statistically significant for both 
EQ-5D (0.06, p= 0.0300) and SF-6D (0.23, p< 0.001). EQ-5D and SF-6D utilities were 
moderately correlated at 12 months (r= 0.68, p< 0.0001) but not during admission 
(r= 0.12, p= 0.2183). Ceiling effect was observed in EQ-5D utility scores, whereby 
22% and 29% of patients reported the best possible EQ-5D health state during 
admission and 12 months, respectively. Only 3% recorded the highest SF-6D utility 
at 12 months. ConClusions: Consistent with past studies, utility scores of ACS 
patients calculated by EQ-5D (Malaysian value set) and SF-6D (Brazier algorithm) 
resulted in different utility values, magnitude of change and extent of ceiling 
effect. Properties of patient reported outcome instruments should also be consid-
ered when selection utility measures for cost-effectiveness studies.
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objeCtives: With a lack of an essential evidence on utilities to support cost-effec-
tiveness analysis of hypertension management in Vietnam, we aimed to gather 
data on health utilities for hypertensive patients and identify predictors of util-
ity. Methods: Hypertensive patients, from 40 to 80 years old visiting the hospital 
were invited to take a survey. Short-form 36 version 2 translated into Vietnamese 
was used to interview patients. We applied a specific published model to measure 
utilities, that explains a reasonable share of variance, especially in those cases when 
only relatively small differences in health are expected. Results: 712 patients were 
included in the study. Mean utility of these patients was 0.72 +/- 0.14. Controlling 
and pharmacy/IV therapy services ($9,484). Average cost per patient in all cat-
egories at 1-year post-AIS increased significantly from the pre-admission period. 
Diagnostic/lab services expenditures increased $20,225; pharmacy/IV therapy 
services increased $6,864; and outpatient visits increased $2,484; all p-values < 
0.001. Compared to the overall AIS patients, the early readmitted patients expe-
rienced higher resource utilization and expenditures. ConClusions: Economic 
burden of Medicare AIS patients is substantial. Resource utilization and direct 
costs were highest during the first 30 days of AIS hospitalization and doubles in 
the first year. Costs significantly increased in the year following stroke compared 
to the pre-admission year.
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objeCtives: This study quantified the total direct healthcare costs of aortic and 
mitral valvular disease to insurers and patients, stratified by asymptomatic and 
symptomatic disease status. Methods: Using 1996-2011 data from the Medical 
Expenditure Panel Survey (MEPS), a large, nationally-representative database from 
the US, this study performed descriptive analyses of the total annual healthcare 
costs to insurers and patients for aortic and mitral valve disease. The healthcare 
costs were reported at the individual and US aggregate levels. Individuals with aortic 
and mitral valve disease were identified by International Classification of Disease 
Codes, 9threvision and stratified as either symptomatic or asymptomatic based on 
the presence of comorbid conditions. Results: The MEPS database included 148 
patients with aortic disease and 1,057 with mitral valve disease. Asymptomatic 
patients comprised 64% and 70% of the population for aortic disease and mitral 
valve disease, respectively. Symptomatic aortic disease patients incurred higher 
overall annual healthcare direct costs per patient compared to asymptomatic 
patients ($30,146 vs. $16,065). Symptomatic mitral valve disease patients incurred 
greater annual healthcare costs per patient compared to asymptomatic patients 
($14,054 vs. $7,198). Because these were direct costs, the majority of the health-
care expenditures were borne by the insurer (range 79% to 90% based on type of 
disease and symptom status) rather than the patient. When aggregated to the US 
population, the overall annual direct cost was $4.5 billion and $10 billion for aortic 
disease and mitral valve disease, respectively. Approximately 75% and 52% of the 
total annual direct cost was attributed to symptomatic aortic valve and mitral valve 
disease patients, respectively. ConClusions: These findings indicate that the total 
direct healthcare costs of valvular disease are quite large. Symptomatic patients 
incur disproportionately greater healthcare costs, possibly due to costly surgical 
interventions required to treat their valvular disease.
CardioVasCUlar disorders – Patient-reported outcomes & Patient  
Preference studies
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PersistenCe and ComPlianCe WitH liPid- loWering drUgs in Patients 
WitH CHroniC kidney disease
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objeCtives: Among individuals suffering from chronic kidney disease (CKD) newly 
treated with lipid-lowering drugs (LLD): (1) to estimate persistence with LLD one 
year after treatment initiation; (2) among those persisting, to estimate compliance 
in the year following LLD initiation; (3) to identify factors associated with persis-
tence and with compliance. Methods: Using Quebec administrative databases we 
carried out a cohort study of individuals aged ≥ 18 who had started a LLD between 
January 1, 2000 and December 31, 2011. Individuals still undergoing treatment with 
any LLD one year after their first claim were considered persistent. Of these, we 
considered compliant those with a supply of drugs for ≥ 80% of days. We identified 
factors associated with persistence and with compliance using modified Poisson 
regression. Results: Among 14,607 eligible individuals, 80.7% were persistent and 
88.7% of these were compliant with their LLD. Individuals with low (Prevalence ratio: 
1.03; 95%IC: 1.01-1.06) and medium socioeconomic status (SES) (1.04; 1.02-1.05) com-
pared with those with high SES, treated by a nephrologist (vs. general practitioner) 
(1.06; 1.04-1.09), who had hypertension (1.04; 1.02-1.06), diabetes (1.04; 1.03-1.06), 
stroke (1.09; 1.07-1.12) or coronary disease (1.07; 1.05-1.09) were more likely to be 
persistent. Individuals more likely to be compliant were aged ≥ 66 (vs. 18-65) (1.04; 
1.01-1.07), had low (vs. high) SES (1.08; 1.06-1.10), and had ≥ 12 (vs. < 7) distinct drugs 
(1.03; 1.0-1.05), had been hospitalized (1.04; 1.02-1.06) or had stroke (1.04; 1.03-1.06) 
in the year prior to LLD treatment initiation. ConClusions: One year after LLD 
initiation, 28% of individuals with CKD were either no longer taking their treatment 
or had not been compliant to it. Results could help target individuals who need help 
to better manage their LLD treatment.
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inertia or aCtUal sWitCHing on mediCaton adHerenCe and eConomiC 
Well-being of mediCare benefiCiaries enrolled in Part d Plans
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objeCtives: It is not well understood the relative impacts of switching (from brand 
name drug to generic drug or plan switching) and consumer inertia on medication 
non-adherence and economic well-being for individuals with at least four most 
common chronic conditions: diabetes, hypertension, heart disease and psychiatric 
problem. The goal of the current study is to examine the whether switching decision 
or consumer inertia impact medication adherence and/or economic well-being of 
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objeCtives: Despite the American Heart Association’s interest in research on 
the determinants of health-related quality of life (HRQoL) among Acute Coronary 
Syndrome (ACS) survivors, little is known about trajectories of HRQoL post-ACS. 
We sought to identify such longitudinal patterns, and their predictors, over the 
6 months post-ACS discharge. Methods: We used data from the Transitions, 
Risks, and Actions in Coronary Events – Center for Cardiovascular Outcomes and 
Education (TRACE-CORE) prospective cohort of patients hospitalized with ACS. 
HRQoL was measured using the Seattle Angina Questionnaire (SAQ) at the index 
hospitalization and at 1-, 3 -, and 6-months post-discharge. The quality of life 
subscore of the SAQ ranges 1-100 with higher scores indicating better HRQoL. We 
used trajectory analysis to identify subgroups of patients with distinctive 6-month 
post-discharge HRQoL patterns, and predictors of different trajectories. Results: 
Participants (N= 920) had mean age 63 (SD 11) years, 34% were female, and 
83% non-Hispanic white. We identified 3 HRQoL trajectories (FAIR, GOOD, and 
EXCELLENT HRQoL) consisting of 12.1%, 53.8% and 34.1% of participants, respec-
tively: FAIR (baseline average HRQoL = 38.8, and remaining low over the 6-month 
follow-up); GOOD (baseline average = 62.6 and increasing modestly over time); 
and, EXCELLENT (baseline average = 87.0 and remaining high). With FAIR HRQoL 
as the referent, we found that older age predicted better HRQoL (OR per year for 
GOOD = 1.09 and for EXCELLENT = 1.18) as did non-Hsipanic white race/ethnic-
ity (OR for GOOD = 3.01; for EXCELLENT = 4.21) and male sex (OR for GOOD= 1.17 
p= 0.56, for EXCELLENT = 2.57). [All p < 0.05, except as noted.] ConClusions: On 
average, HRQoL was relatively stable over time, and no trajectories with decreasing 
HRQoL were found. Early HRQoL scores could direct resources to improve HRQoL 
over the first 6 months post-ACS.
CardioVasCUlar disorders – Health Care Use & Policy studies
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imPlementation of tHe ameriCan diabetes assoCiation’s standards 
of mediCal Care: tHe Case of statin Utilization in tHe elderly WitH 
diabetes
Li M., Lu K., Maxwell W.D., Schulz R.M.
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objeCtives: Since 2005, the American Diabetes Association’s (ADA’s) Standards 
of Medical Care in Diabetes have recommended that elderly diabetic patients 
with overt cardiovascular disease (CVD) or CVD risk factors should take statins 
to manage lipid levels. The objectives of this study were to 1) provide national 
estimates of statin utilization, and 2) identify predictors of statin use in elderly 
Medicare beneficiaries with diabetes to whom the ADA’s Standards of Medical Care 
apply. Methods: This study was a pooled cross-sectional study of the Medicare 
Current Beneficiaries Survey (MCBS) from 2006 to 2010. Sampling weights were 
applied to generate national estimates. Weighted logistic regression was performed 
to identify predicators of statin use. Results: Among 8,539 person-years of elderly 
diabetic patients, 8,115 (94.69%, weighted percentage) were eligible for statin therapy 
according to the ADA’s Standards of Medical Care. In 2006, 2007, 2008, 2009, and 2010, 
55.27%, 53.30%, 53.23%, 57.86%, and 60.70% of eligible diabetics used statins, respec-
tively. Predictors of non-use of statin included: being non-Hispanic black (odds ratio 
[OR]: 0.69; 95% confidence interval [CI]: 0.56-0.84), living in non-metropolitan areas 
(OR: 0.78; 95% CI: 0.69-0.88), being underweight, with a body mass index of 18.5 or 
under, (OR: 0.27; 95% CI: 0.13-0.54), having one or more comorbidities in addition to 
CVD (OR: 0.81; 95% CI: 0.68-0.95), and having CVD risk factors (OR: 0.59; 95% CI: 0.51-
0.67). ConClusions: A 10% increase in statin use was observed among diabetic 
patients who satisfied ADA’s criteria for statin use between 2006 and 2010. Still, 
approximately 40% of eligible individuals with diabetes were not taking statins in 
2010. For elderly Medicare beneficiaries with diabetes, healthcare providers should 
be aware of patient factors associated with statin non-use and provide interventions 
to improve prescribing patterns and patient adherence.
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bACkgRound: Obesity is a chronic condition and its clinical and economic conse-
quences are very concerning. Obesity and its co-morbidities were associated with 
USD 2.1 billion annually costs in the Brazilian Public Health System. According to 
a National Survey there are 22 million people in Brazil with BMI > 30kg/m2. Also 
there are 13.5 million diabetic people, many of them being obese objeCtives: To 
describe epidemiology, treatment patterns, resource use and associated costs of 
morbid obese patients in the list, waiting to receive surgical treatment for surgery 
in order to quantify the clinic and economic burden of not providing surgical treat-
ment to eligible patients Methods: Non-interventional, single center, retrospec-
tive cohort with medical chart review of 300 patients who met eligibility criteria, 
having their registry data extracted and outcomes followed-up for up to 12-months 
post-bariatric-surgery Results: The mean time in the waiting list was 751.76 days. 
BMI mean at baseline was 46,53 kg/m2 (95% CI 45,67-47,39); 43,78 kg/m2 (95% CI 
42,98-44,59) at surgery and 30,91 kg/m2 (95% CI 30,29-31,55) at 12-months follow-up. 
195(65%) of patients presented hypertension at baseline, which 92,8% presented 
improvement/resolution 12-months after surgery. 70(23,3%) presented dyslipidemia, 
with resolution of 94,3% after 12-months. 55(18,33%) presented diabetes, with res-
olution of 94,3% after 12-months. 37 (12,33%) patients increased BMI during the 
wait list., these patients presented lower comorbidities resolution rates compared 
to patients who maintained or reduced their BMI in the wait list ConClusions: 
Analysis demonstrated high comorbidities resolution rates after 12 months of follow 
for age, sex, blood pressure (BP) stage and history of stroke, we found that the utili-
ties in older patients were lower than those of the younger groups, and statistically 
significantly differing if compared the extremes of youngest and oldest groups 
were considered (p= 0.03). Utility in males was higher than in females (p= 0.002). 
Patients with a history of stroke exhibited lower utility than patients without such 
history, although not statistically significant (p= 0.73). Patients with more than 
3 comorbidities had lower utilities than patients without comorbidity (p= 0.01). 
Statistically in significantly relatively higher BP was associated with lower utility 
at 0.734, 0.726 or 0.712 in the groups with target BP, stage 1 and 2, respectively (p= 
0.422). ConClusions: Mean utility was estimated at 0.72 in hypertensive patients 
in Vietnam. In contrast to BP staging and history of stroke, gender was found as a 
statistically significant predictor of utility. In addition, patients who experience 
more than 3 comorbidities or older than 70 had statistically significant lower utili-
ties.
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objeCtives: There is limited information on drivers of utilities in patients with 
chronic heart failure (CHF). We analyzed determinants of utility in CHF and driv-
ers of change over one year in a large sample from clinical practice. Methods: 
We included 5334 patients from the Swedish Heart Failure Registry with EQ-5D 
information available following inpatient or outpatient care during 2008 to 2010; 
3495 had 1-year follow-up data. We applied ordinary least squares (OLS) and two-
part models for utility at inclusion, OLS regression for change over one year, all 
with robust standard errors. We assessed predictive accuracy of both models using 
cross-validation. Results: Mean age was 73 years, 65% were male, 19% had a left 
ventricular ejection fraction ≥ 50%, 23% 40-49%, 27% 30-39%, and 31% < 30%. For both 
models, utility at inclusion was negatively affected by female gender, increasing 
age, increasing New York Heart Association (NYHA) class, preserved left ventricular 
ejection fraction, lung disease, diabetes, and use of nitrates, antiplatelets or diuret-
ics. Higher systolic blood pressure and haemoglobin levels and use of angiotensin 
converting enzyme inhibitors/angiotensin receptor blockers or beta-blockers were 
associated with increased utility. A significant interaction between age category 
and functional class indicated that patients in the youngest age group are more 
severely affected by worsening functional status than older patients. The OLS model 
performed slightly better than the two-part model on a population level and for 
capturing utility ranges. Change in utility over one year was influenced by age, 
gender, disease duration, and (measured at inclusion) NYHA class, blood pressure, 
ischemic heart disease, lung disease, angiotensin converting enzyme inhibitors/
angiotensin receptor blockers and antiplatelets. ConClusions: Utilities in CHF 
and their change over time are influenced by diverse demographic and clinical 
factors. Our findings can be used to target clinical interventions and for economic 
evaluations of new therapies.
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deteCt CHange
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objeCtives: The TCM-SAQ was a valid and reliable syndrome-specific instruction 
to assess quality of life (QoL) for angina treated by traditional Chinese medicine. 
However, its ability to detect change has not been discussed. This study was aimed 
to investigate the ability of detecting change over time of the TCM-SAQ. Methods: 
The data is performed from an Random Clinical Trail. Patient diagnosed with angina 
pectoris were enrolled in ten Chinese medical hospitals in the northeast of China, 
from June, 2011 to May, 2012. All enrolled patients were treated by Chinese herbs 
combined with aspirin and Lipitor for 8 weeks; nitrates were used to release angina 
attack. Angina symptoms (frequency, duration, pain degree) were used to assess the 
therapeutic efficiency; lower scores represent better angina conditions. TCM-SAQ 
was tested at the enrollment and 8th weeks of the treatment, higher scores means 
better quality of life. Results: Analysis is based on 240 patients (age 60±7years; 
111 male, 52%). The disease history is 3.5±3.5 years. Seventy-nine (32.9%) patients 
have at least one comorbidity. The average angina attack times per week before 
the treatment is 6.28, and 2.36 after eight weeks’ treatment, which declined 3.97 
times; the average angina attack duration is 5.73 before, and 2.56 after, and angina 
score declined 4.1 after the treatment. TCM-SAQ shows a significant improved of 
QoL in each domain as well as the angina condition changes (P= 0.000). Of all those 
patients, 64 patient’s (26.7%) angina condition remained unchanged, and 176 (73.3%) 
improved. Therapeutic effective patients show a better QoL than invalid patients. 
TCM-SAQ can detect the differences between effective and invalid patients in 
domains(p= 0.000). ConClusions: The TCM-SAQ has a good ability to detect clini-
cal change over time in individuals, and it also can detect the differences between 
known groups. In the future, we need to determine the minimal clinic differences 
of TCM-SAQ.
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